Perspective Therapeutics, Inc.

CATX Healthcare Medical Devices

Perspective Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $884,000.00, down 39.2% from fiscal 2024.

Revenue
−72.1%
EPS
+24.1%
Free cash flow
−66.1%
Total debt
−3.57%

Quarter to June 2026, against a year earlier

0.84 0.05 +6.33%
Market cap
$90.0M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
3/9
Altman Z
−0.59
Beneish M
0.59
Dividend safety
n/a

Perspective Therapeutics, Inc. (CATX) P/E ratio

Alert me on P/E ratio

Perspective Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
41 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
LUCD Lucid Diagnostics Inc. compare n/m
APYX Apyx Medical Corporation compare n/m
SERA Sera Prognostics, Inc. compare n/m
CATX Perspective Therapeutics, Inc. n/m
NYXH Nyxoah SA compare n/m
LUNG Pulmonx Corporation compare n/m
OM Outset Medical, Inc. compare n/m
HYPR Hyperfine, Inc. compare n/m
ZOMDF Zomedica Corp. compare n/m
Medical Devices industry median 25.6×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on CATX